Drug Profile
CKD 386
Alternative Names: CKD-386; CKD-386(2); D 013/D 326/D 337; D013/D326/D337 - Chong Kun Dang PharmaceuticalLatest Information Update: 14 Nov 2023
Price :
$50
*
At a glance
- Originator Chong Kun Dang
- Class Antihyperlipidaemics; Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Dyslipidaemias; Hypertension
Most Recent Events
- 26 Sep 2023 Chong Kun Dang Pharmaceutical completes a phase I trials in Dyslipidaemias and Hypertension (In volunteers, Combination therapy) in South Korea (PO) (NCT05698043)
- 17 Jul 2023 Phase-I clinical trials in Dyslipidaemias (In volunteers, Combination therapy) in South Korea (PO) (NCT05698043)
- 17 Jul 2023 Phase-I clinical trials in Hypertension (Combination therapy, In volunteers) in South Korea (PO) (NCT05698043)